Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 18/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751911 | 1.00 | ERBB2 (0.56) | ERBB2CASP3SENP8SENP7SENP6 | |
| SCHEMBL4504715 | 0.86 | ERBB2 (0.44) | ERBB2 | |
| SCHEMBL4056631 | 0.86 | ERBB2 (0.56) | ERBB2 | |
| SCHEMBL4056632 | 0.86 | ERBB2 (0.56) | ERBB2 | |
| SCHEMBL4504713 | 0.86 | ERBB2 (0.44) | ERBB2 | |
| SCHEMBL5749738 | 0.84 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL5749733 | 0.84 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL6579995 | 0.84 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL6579991 | 0.84 | ERBB2 (0.55) | ERBB2 | |
| SCHEMBL5761527 | 0.84 | ERBB2 (0.50) | ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984653-B2 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-10 | — | — | US | disclosed |
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1439178-A1 | HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040116330-A1 | Diagnosing or specifying a growth factor receptor expressed in cancer cells, and selectively inhibiting all or a part of the growth factor receptor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| CN-1487935-A | Improved water-soluble pharmaceutical compositions | ����ҩƷ��ҵ��ʽ���� | 2004-04-07 | — | — | CN | disclosed |
| CN-1487936-A | Medicinal compositions having improved absorbability | ����ҩƷ��ҵ��ʽ���� | 2004-04-07 | — | — | CN | disclosed |
| US-6716863-B2 | TYROSINE KINASE INHIBITORS; ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040024035-A1 | Heterocyclic compounds, their production and use | TASAKA AKIHIRO (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1350793-A1 | MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| EP-1350792-A1 | MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER | Takeda Chemical Industries, Ltd. (JP) | 2003-10-08 | — | — | EP | disclosed |
| CN-1444582-A | Heterocyclic compound, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-09-24 | — | — | CN | disclosed |
| EP-1268473-A1 | OXAZOLE DERIVATIVES AND THEIR USES AS TYROSINE KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020173526-A1 | Heterocyclic compounds their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| WO-2001077107-A1 | OXAZOLE DERIVATIVES AND THEIR USES AS TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024035-A1 | Heterocyclic compounds, their production and use | ABL1, ROS1, MAPK1 | ERBB2 6/4885CASP3 1548/4885SENP8 3696/4885 |
| US-20020173526-A1 | Heterocyclic compounds their production and use | ABL1, ROS1, MAPK1 | ERBB2 8/4885CASP3 1703/4885SENP8 3661/4885 |
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | ABL1, JAK1, BTK | ERBB2 17/4885CASP3 1675/4885SENP8 3129/4885 |
| US-20040058956-A1 | Pharmaceutical composition having an improved water solubility | ERBB2, EGFR, ABCG2 | ERBB2 1/4885CASP3 3385/4885SENP8 1937/4885 |
| US-20040138160-A1 | Preventive/therapeutic method for cancer | EGFR, ERBB2, ERBB3 | ERBB2 2/4885CASP3 791/4885SENP8 2555/4885 |
| US-20040053972-A1 | Medicinal compositions having improved absorbability | EGFR, ERBB2, ERBB3 | ERBB2 2/4885CASP3 1963/4885SENP8 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.